Inovio Pharmaceuticals (INO) AI Stock Analysis

• Market Cap: $125.95M
• Dividend Yield: N/A
• Average Volume (3M): 1.99M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: -69.19%
• EPS Growth: 48.94%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 53,142,662
• 10 Day Avg. Volume: 2,277,378
• 30 Day Avg. Volume: 1,991,102
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 231.04
• Enterprise Value/Gross Profit: -20.05
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $6.96
• Price Target Upside: 170.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 51 Neutral
• Price Target: $2.50 ▼(-2.72% Downside)

Inovio Pharmaceuticals' overall stock score reflects a challenging financial position with persistent losses and negative cash flows. Despite technical indicators showing bullish momentum, the stock is overbought, and valuation metrics are unattractive due to ongoing losses. The earnings call provided some optimism with progress in regulatory submissions and cost reductions, but concerns about cash reserves and competition remain significant.

Positive Factors

Clinical Efficacy

The increase in complete response subjects for years two and three highlights a continued deepening of effect of INO-3107 in the overall population.

Regulatory Progress

INO-3107 has been granted Breakthrough Therapy designation for the treatment of recurrent respiratory papillomatosis (RRP) by the FDA.

Safety Profile

No treatment-emergent serious adverse events were identified in the trial, which increases confidence in the safety of INO-3107.

Negative Factors

Financial Needs

The company may need to raise additional capital within the next 12 months.

Market Competition

A potential competitor for the treatment of recurrent respiratory papillomatosis (RRP) has a PDUFA date of August 27, 2025.

Regulatory Uncertainty

INO-3107 may not gain regulatory approval in RRP or meet sales forecasts.

Inovio Pharmaceuticals Business Overview & Revenue Model

Company Description

Inovio Pharmaceuticals (INO) is a biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company specializes in its proprietary platform technology that delivers therapeutic DNA plasmids into the body, harnessing the immune system to generate a targeted response. Inovio's core products include its investigational therapies for various cancers and its work on vaccines against infectious diseases, including COVID-19.

How the Company Makes Money

Inovio Pharmaceuticals generates revenue primarily through research and development (R&D) collaborations, government grants, and partnerships with pharmaceutical companies. The company often engages in strategic alliances to co-develop its products, which can provide upfront payments, milestone payments, and royalties on future product sales. Additionally, Inovio may receive funding from government entities and non-profit organizations for specific projects, especially those related to public health needs. The company is also focused on advancing its clinical studies, which could lead to product approvals and subsequent commercialization, contributing to its revenue streams.

Inovio Pharmaceuticals Financial Statement Overview

Summary

Inovio Pharmaceuticals is facing significant financial challenges, characterized by persistent losses, negative cash flows, and lack of revenue growth. While the balance sheet shows a strong equity position, the lack of profitability and reliance on financing raise concerns about the company's financial health.

Income Statement

Inovio Pharmaceuticals exhibits a challenging financial position with consistent negative net income and EBIT over the years. The company shows no revenue growth and gross profit margins are negative, indicating cost management issues or insufficient revenue to cover costs. The absence of gross profit and negative EBIT margins reflect the company's ongoing struggle with profitability.

Balance Sheet

The balance sheet reveals a relatively stable equity position with stockholders' equity being significantly higher than total debt, resulting in a low debt-to-equity ratio. However, the company has been heavily reliant on equity financing, as indicated by the substantial stockholders' equity compared to total assets. Despite the strong equity base, the company has not converted this into profitability or growth.

Cash Flow

Cash flow analysis indicates a negative operating and free cash flow, showing difficulties in generating cash from operations. The company has relied on financing activities to sustain operations, which may not be sustainable long-term. The absence of positive free cash flow growth further highlights challenges in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	182.34K	217.76K	832.01K	10.26M	1.77M	7.41M
Gross Profit	-2.10M	-2.91M	-2.67M	4.77M	-2.96M	-86.83M
EBITDA	-25.12B	-103.95M	-130.39M	-270.90M	-296.56M	-149.56M
Net Income	-44.90B	-107.25M	-135.12M	-279.82M	-303.66M	-166.41M
Balance Sheet
Total Assets	68.24M	113.20M	170.95M	348.53M	495.94M	539.77M
Cash, Cash Equivalents and Short-Term Investments	47.55M	94.11M	145.29M	253.00M	401.31M	411.64M
Total Debt	10.66M	11.87M	30.21M	32.07M	33.02M	39.05M
Total Liabilities	39.71M	44.69M	53.60M	126.17M	96.27M	78.63M
Stockholders Equity	28.53M	68.50M	117.35M	222.36M	399.67M	461.14M
Cash Flow
Free Cash Flow	-132.06B	-104.56M	-124.69M	-217.18M	-216.94M	-179.50M
Operating Cash Flow	-132.06B	-104.08M	-124.37M	-216.22M	-215.71M	-177.98M
Investing Cash Flow	5.28B	104.07M	87.36M	109.59M	-175.34M	-58.80M
Financing Cash Flow	-3.94M	51.48M	5.00M	81.84M	211.50M	465.28M

Inovio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.57
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INO, the sentiment is Positive. The current price of 2.57 is above the 20-day moving average (MA) of 1.87, above the 50-day MA of 1.70, and above the 200-day MA of 2.14, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 77.73 is Negative, neither overbought nor oversold. The STOCH value of 89.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INO.

Inovio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	61 Neutral	$102.47M	―	-46.28%	―	-33.00%	54.91%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
INO	51 Neutral	$125.95M	―	-140.12%	―	-69.19%	48.94%
SAVA	43 Neutral	$110.14M	―	-88.95%	―	―	-553.86%
IFRX	41 Neutral	$107.41M	―	-62.38%	―	178.84%	-40.60%
ABOS	36 Underperform	$82.38M	―	-75.71%	―	―	-103.31%
JSPR	35 Underperform	$45.51M	―	-146.87%	―	―	-17.96%

Inovio Pharmaceuticals Corporate Events

Inovio Pharmaceuticals Announces Public Offering Agreement

On July 2, 2025, INOVIO Pharmaceuticals entered into an underwriting agreement with Piper Sandler & Co. for a public offering of 14,285,715 shares of common stock and accompanying Series A and B warrants. The company expects net proceeds of approximately $22.5 million from the offering, which is anticipated to close around July 7, 2025, subject to customary conditions. This move is expected to bolster INOVIO’s financial position, potentially impacting its market presence and stakeholder interests.